BPC-157 vs TB-500: Which Is Better for Recovery?

BPC-157 and TB-500 are the two most studied recovery peptides in the research community — and the question "which is better?" misses the more important point: they work differently, on different mechanisms, and are genuinely complementary rather than redundant. This comparison covers what each does, where each excels, and why they're so often used together.

Aspect	BPC-157	TB-500
Origin	Derived from human gastric juice protein BPC	Synthetic fragment of Thymosin Beta-4 (endogenous protein)
Size	15 amino acids	17 amino acids (fragment of 43-AA protein)
Primary mechanism	NO system modulation, VEGF upregulation, fibroblast activation at injury site	Actin regulation, systemic angiogenesis, cell migration to injury
Distribution	Works primarily locally — concentrates at the injection site and injury	Distributes systemically — reaches injuries throughout the body from any injection site
Gut applications	Yes — oral BPC-157 for IBD, ulcers, leaky gut	No documented gut-specific use
Cardiac research	Some cardioprotective data in animal models	Stronger cardiac data — studied in porcine ischemic heart models
Neurological effects	Dopamine/serotonin stabilisation; some neuroprotective research	Remyelination research; nerve regeneration studies
Typical dose	200–500 mcg per injection	2–5 mg per injection (weekly or twice weekly)
Injection frequency	Once or twice daily	1–2x per week (longer half-life)
Tumour growth concern	Theoretical only — no confirmed evidence	More frequently cited concern — TB-500's systemic distribution and pro-angiogenic effects raise slightly more caution

Where BPC-157 Wins

Gut health — BPC-157 is the only compound in this class with established oral bioavailability for gut mucosal applications. For IBD, gastric ulcers, and leaky gut, BPC-157 oral is the protocol.

Local injury focus — its short half-life and local mechanism mean injecting near an injury produces concentrated local effects that TB-500's systemic distribution doesn't replicate.

Neurotransmitter stabilisation — BPC-157's dopamine and serotonin system effects are better characterised than TB-500's neurological research.

Longer research history — Sikiric's lab has been publishing on BPC-157 since 1993. The evidence base is more extensive.

Where TB-500 Wins

Systemic distribution from any injection site — you don't need to inject near the injury. This matters for injuries that are difficult to access (deep muscle, spinal structures).

Cardiac tissue data — TB-500 (full Thymosin Beta-4) has been studied in porcine ischemic heart models with positive findings for cardiac muscle repair.

Remyelination research — TB-500's nerve regeneration and remyelination studies are more developed than BPC-157's neurological data.

Once or twice weekly dosing — longer effective half-life means less frequent injections for equivalent systemic coverage.

The Wolverine Stack: Why They're Better Together

The combination of BPC-157 and TB-500 — popularised as the "Wolverine Stack" and discussed on the Joe Rogan Experience — is mechanistically additive rather than redundant. The two compounds target different points in the healing cascade:

BPC-157 works at the injury site — recruiting fibroblasts, reducing local inflammation, and stimulating local blood vessel formation
TB-500 improves systemic blood flow — promoting the migration of repair cells (platelets, immune cells, fibroblasts) from circulation to the injury location
Together, BPC-157 creates the repair environment locally while TB-500 sends the cellular resources systemically — a genuinely additive combination
The Wolverine Stack (BPC-157 + TB-500) is the most widely discussed recovery protocol in the peptide research community and was discussed by Joe Rogan and Andrew Huberman on JRE episodes
Typical stack: BPC-157 (250–500 mcg daily) + TB-500 (2–5 mg twice weekly), 8–12 week cycle

BPC-157 at Base Peptides TB-500 at Base Peptides

Research use only. Neither BPC-157 nor TB-500 is FDA-approved for human use. All comparison data is derived from animal studies. This article is for educational purposes only.

All BPC-157 Guides

→ BPC-157 Full Research Profile → BPC-157 Dosage Protocol → How Long Does BPC-157 Take to Work?→ BPC-157 Side Effects → Where to Inject BPC-157 → How to Reconstitute BPC-157 → Mechanism of BPC-157 → BPC-157 Studies Explained

Developed & Edited by Brian Gossett

Created with AI-assisted research and drafting. Sources, conclusions, and final content reviewed by the author.

Founder & Biotechnology Research Industry Entrepreneur

20+ years of entrepreneurial experience • Peptide & biotechnology industry experience

View Staff Profile →

Disclosure: Brian is the founder of Base Peptides, a large research peptide supplier. Full disclosure.

Found an error? Review our Corrections Policy or contact us.